Zoetis Inc. Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
Zoetis Inc. (ZTS) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price of $129.13 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice · last filed 2026-08-06
- Zoetis Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2026-03-31 was $129.13, a 17.56% decline year-over-year.
- Zoetis Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2025-03-31 was $156.64, a 20.14% decline year-over-year.
- Zoetis Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2024-03-31 was $196.14, a 21.02% increase year-over-year.
- Zoetis Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2023-03-31 was $162.07, a 19.49% decline year-over-year.
- Zoetis Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2025 was $156.80, a 19.79% decline from fiscal 2024.
- Zoetis Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2024 was $195.49, a 20.58% increase from fiscal 2023.
- Zoetis Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2023 was $162.12, a 19.44% decline from fiscal 2022.
- Zoetis Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2022 was $201.23, a 25.20% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2026-06-30 | $129.13 10-Q · filed 2026-08-06 | |||
| 2026-03-31 | $129.13 10-Q · filed 2026-05-07 | |||
| 2025-12-31 | $156.80 10-K · filed 2026-02-12 | |||
| 2025-09-30 | $156.80 10-Q · filed 2025-11-04 | |||
| 2025-06-30 | $156.80 10-Q · filed 2025-08-05 | |||
| 2025-03-31 | $156.64 10-Q · filed 2025-05-06 | |||
| 2024-12-31 | $195.49 10-K · filed 2025-02-13 | |||
| 2024-09-30 | $195.84 10-Q · filed 2024-11-04 | |||
| 2024-06-30 | $196.04 10-Q · filed 2024-08-06 | |||
| 2024-03-31 | $196.14 10-Q · filed 2024-05-02 | |||
| 2023-12-31 | $162.12 10-K · filed 2024-02-13 | |||
| 2023-09-30 | $162.12 10-Q · filed 2023-11-02 | |||
| 2023-06-30 | $162.12 10-Q · filed 2023-08-08 | |||
| 2023-03-31 | $162.07 10-Q · filed 2023-05-04 | |||
| 2022-12-31 | $201.23 10-K · filed 2023-02-14 | |||
| 2022-09-30 | $201.23 10-Q · filed 2022-11-03 | |||
| 2022-06-30 | $201.23 10-Q · filed 2022-08-04 | |||
| 2022-03-31 | $201.30 10-Q · filed 2022-05-05 | |||
| 2021-12-31 | $160.73 10-K · filed 2022-02-15 | |||
| 2021-09-30 | $160.73 10-Q · filed 2021-11-04 | |||
| 2021-06-30 | $160.73 10-Q · filed 2021-08-05 | |||
| 2021-03-31 | $160.62 10-Q · filed 2021-05-06 | |||
| 2020-12-31 | $144.13 10-K · filed 2021-02-16 | |||
| 2020-09-30 | $143.23 10-Q · filed 2020-11-05 | |||
| 2020-06-30 | $143.23 10-Q · filed 2020-08-06 | |||
| 2020-03-31 | $144.03 10-Q · filed 2020-05-06 | |||
| 2019-12-31 | $87.87 10-K · filed 2020-02-13 | |||
| 2019-09-30 | $87.77 10-Q · filed 2019-11-07 | |||
| 2019-06-30 | $87.77 10-Q · filed 2019-08-06 | |||
| 2019-03-31 | $87.51 10-Q · filed 2019-05-02 | |||
| 2018-12-31 | $73.32 10-K · filed 2019-02-14 | |||
| 2018-09-30 | $73.32 10-Q · filed 2018-11-01 | |||
| 2018-06-30 | $73.32 10-Q · filed 2018-08-02 | |||
| 2018-03-31 | $73.26 10-Q · filed 2018-05-02 | |||
| 2017-12-31 | $55.17 10-K · filed 2018-02-15 | |||
| 2017-10-01 | $55.13 10-Q · filed 2017-11-02 | |||
| 2017-07-02 | $55.09 10-Q · filed 2017-08-08 | |||
| 2017-04-02 | $55.01 10-Q · filed 2017-05-04 | |||
| 2016-12-31 | $42.51 10-K · filed 2017-02-16 | |||
| 2016-10-02 | $42.32 10-Q · filed 2016-11-03 | |||
| 2016-07-03 | $41.89 10-Q · filed 2016-08-05 | |||
| 2016-04-03 | $41.83 10-Q · filed 2016-05-06 | |||
| 2015-12-31 | $46.01 10-K · filed 2016-02-24 | |||
| 2015-09-27 | $46.01 10-Q · filed 2015-11-05 | |||
| 2015-06-28 | $45.99 10-Q · filed 2015-08-06 | |||
| 2015-03-29 | $45.92 10-Q · filed 2015-05-07 | |||
| 2014-12-31 | $30.97 10-K · filed 2015-02-27 | |||
| 2014-09-28 | $30.97 10-Q · filed 2014-11-10 | |||
| 2014-06-29 | $30.89 10-Q · filed 2014-08-12 | |||
| 2014-03-30 | $30.89 10-Q · filed 2014-05-13 | |||
| 2013-12-31 | $26.11 10-K · filed 2014-03-26 | |||
| 2013-09-29 | $26.11 10-Q · filed 2013-11-13 | |||
| 2013-06-30 | $26.05 10-Q · filed 2013-08-14 | |||
| 2013-03-31 | $26.00 10-Q · filed 2013-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |